We also found lower CD33 expression levels in s/tAML compared to de novo AML patients (Supplementary Fig. S7), which might indicate reduced efficacy of GO in these patients and raises the question of applying higher dosages in selected patients. Here, CD33 is linked to acute myeloid leukemia.